Cancer Frontline

September 2018
Archive

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
encompass a spectrum of diseases characterized by an overproduction of
immature blood cells, resulting in a lack of healthy, mature blood
cells in patients.

Unfortunately, the majority of patients with these diseases are not
cured with currently available therapies, so MD Anderson’s MDS and AML
Moon Shot™ team has committed to developing new treatment options...